Cue Biopharma (CUE) Scheduled to Post Earnings on Monday

Cue Biopharma (NASDAQ:CUE) will be posting its quarterly earnings results on Monday, April 8th.

Cue Biopharma Stock Performance

Shares of CUE stock opened at $1.85 on Friday. The company’s fifty day simple moving average is $2.11 and its 200-day simple moving average is $2.35. Cue Biopharma has a 52 week low of $1.70 and a 52 week high of $5.12. The company has a current ratio of 3.34, a quick ratio of 3.34 and a debt-to-equity ratio of 0.12. The company has a market cap of $89.99 million, a PE ratio of -1.55 and a beta of 2.02.

Wall Street Analyst Weigh In

Several research firms recently issued reports on CUE. Jefferies Financial Group began coverage on shares of Cue Biopharma in a research note on Wednesday, March 13th. They set a “buy” rating and a $6.00 price target on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $8.00 price target on shares of Cue Biopharma in a research note on Wednesday.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SNC boosted its holdings in shares of Cue Biopharma by 9,270.1% in the 2nd quarter. BNP Paribas Arbitrage SNC now owns 9,089 shares of the company’s stock valued at $33,000 after buying an additional 8,992 shares during the period. Citigroup Inc. acquired a new position in Cue Biopharma during the 2nd quarter valued at about $38,000. Wolverine Trading LLC acquired a new position in Cue Biopharma during the 3rd quarter valued at about $26,000. California State Teachers Retirement System acquired a new position in Cue Biopharma during the 2nd quarter valued at about $42,000. Finally, Mirabella Financial Services LLP acquired a new position in Cue Biopharma during the 1st quarter valued at about $58,000. 35.04% of the stock is owned by institutional investors and hedge funds.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers.